SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: james bravick who wrote (334)10/19/1997 2:05:00 AM
From: Jim Mac   of 1754
 
james: Procedure revs are received the quarter following the actual procedures. Since U.S. volume was about 35,000-40,000 in 1997Q1 (according to Visx Q2 conference call, I believe), and case volume has doubled since then, it's safe to assume we're at the 70,000 quarterly level by now.

By the way, Laser Vision Centers' U.S. case volume doubled from 97Q1 to Q2, and again from 97Q2 to Q3. Beacon's grew 70% from July to August, I believe, and LCA-Vision's grew 44% from 97Q1 to Q2. Visx's astigmatism approval effects are just now kicking in, and Summit is still waiting for its astigmatism approval...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext